RASAL2 and nasopharyngeal carcinoma: For examples, in luminal B breast cancer, lung adenocarcinoma, ovarian cancer, nasopharyngeal carcinoma and bladder cancer, RASAL2 inhibits tumor cell migration and invasion by suppressing RAS signaling pathway and epithelial mesenchymal transition (EMT) 8, 9, 22-24.